Last reviewed · How we verify
NCT06832020
Determinants of Adaptive Behavior Through the Vineland Scale in Pediatric Patients With Severe and Drug-resistant Epilepsy
trial in Epilepsy (Treatment Refractory) in 369 participants. Completed in 11 July 2023.
18 January 2023
Quick facts
| Lead sponsor | Ana Valeria Duarte Oliveira |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 369 |
| Start date | 7 July 2021 |
| Primary completion | 18 January 2023 |
| Estimated completion | 11 July 2023 |
| Sites | 1 location across Brazil |
Conditions studied
- Epilepsy (Treatment Refractory) — all drugs for Epilepsy (Treatment Refractory) →
Sponsor
Ana Valeria Duarte Oliveira
Who can join
Adults 0 to 18, any sex, with Epilepsy (Treatment Refractory). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our interest in studying how pediatric patients develop after epilepsy surgery stems from the fact that difficult-to-control epilepsy causes changes in the brain's formation or functioning, leading some patients to experience slower development compared to others. By gaining a better understanding of how pediatrics patients fare after epilepsy surgery, specifically regarding their independence in daily activities (such as bathing or making the bed), their relationships with family and friends, their mobility, and their speech (whether it is understandable) we can learn more about patient recovery. The goal of this research is to determine whether, 4 years after epilepsy surgery, pediatrics patients show improvements in development. This study is important because it investigates what happens to the development of children who have undergone epilepsy surgery after a long period has passed since the procedure. Research focusing on long-term post-surgical outcomes is necessary, especially in pediatrics, as a brain is not fully developed and requires time to recover after surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06832020
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy (Treatment Refractory)
Currently open trials in the same condition.
- NCT07220161 — Trigeminal Nerve Stimulation of the Treatment of Epilepsy · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06832020 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ana Valeria Duarte Oliveira
- Last refreshed: 18 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06832020.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing